How have NRXPW shares performed in 2024?

NRx Pharmaceuticals' stock was trading at $0.1297 on January 1st, 2024. Since then, NRXPW stock has increased by 15.6% and is now trading at $0.1499. View the best growth stocks for 2024 here .

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,200 shares, a drop of 69.2% from the March 15th total of 3,900 shares. Based on an average daily trading volume, of 20,100 shares, the short-interest ratio is presently 0.1 days. View NRx Pharmaceuticals' Short Interest .

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRXPW

NRx Pharmaceuticals (NRXPW) Stock Price, News & Analysis

→ At first glance, this chart looks like nonsense… (From The TradingPub) (Ad)

Free NRXPW Stock Alerts

$0.15

0.00 (0.00%)

(As of 04/24/2024 ET)

Compare

Today's Range: $0.15
▼
$0.16
50-Day Range: $0.10
▼
$0.33
52-Week Range: $0.05
▼
$0.39

Volume: 24,103 shs
Average Volume: 24,599 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get NRx Pharmaceuticals alerts:

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

NRXPW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRXPW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive NRXPW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NRXPW
CUSIP: N/A
CIK: 1719406
Web: www.nrxpharma.com
Phone: 484 254 6134
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Jonathan C. Javitt M.D. (Age 67)
M.P.H., Co-Founder, Chief Scientist Officer & Chairman
Comp: $873.7k
Mr. Stephen H. Willard Esq. (Age 63)
Acting Corporate Secretary, CEO & Director
Comp: $501.19k
Dr. Riccardo Panicucci Ph.D. (Age 62)
Chief Technology Officer
Comp: $240k
Dr. Seth L. Van Voorhees Ph.D. (Age 63)
Treasurer
Comp: $399.96k
Mr. Richard Clavano Narido (Age 46)
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Suzanne Messere
Investor Relations
Dr. Philip T. Lavin Ph.D. (Age 77)
Chief Methodologist
Dr. Dennis K. McBride Ph.D.
Chief Strategy Officer & Senior Scientist
Mr. Matthew Patrick Duffy (Age 61)
Chief Business Officer

Key Competitors

View All Competitors

NRXPW Stock Analysis - Frequently Asked Questions

How have NRXPW shares performed in 2024?: NRx Pharmaceuticals' stock was trading at $0.1297 on January 1st, 2024. Since then, NRXPW stock has increased by 15.6% and is now trading at $0.1499.
View the best growth stocks for 2024 here.
Are investors shorting NRx Pharmaceuticals?: NRx Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,200 shares, a drop of 69.2% from the March 15th total of 3,900 shares. Based on an average daily trading volume, of 20,100 shares, the short-interest ratio is presently 0.1 days.
View NRx Pharmaceuticals' Short Interest.
How do I buy shares of NRx Pharmaceuticals?: Shares of NRXPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRXPW) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial